A Phase 2 interventional study of LY2189265 and Lifestyle Measures and Placebo solution and Lifestyle Measures in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 46 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-10.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 26th largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 2, and was the 3rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 167 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 119th largest by enrollment of the 232 interventional ones that give a count, is one of 8 that started in 2008, is one of 34 in phase 2, and was the 33rd registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.
Participants in the trial will be randomized to one of the LY2189265 doses (4 doses are planned, range 0.1-1.5 milligram [mg]) or placebo. The main purpose is to assess dose-dependent effect of this new compound on blood glucose over a period of 12 weeks. Therefore, glycosylated hemoglobin (HbA1c) is chosen as the primary efficacy measure. Several other attributes of glycemic control and endocrine function of pancreas will be assessed as secondary objectives. These secondary objectives will be used to compare the effect of the experimental compound and placebo. Since LY2189265 is in early phase of development, comprehensive safety assessment is planned to learn more about possible side-effects and to establish benefit/risk profile of individual doses of the drug. The trial is organized in four phases: screening, lead-in period to establish baseline status of participants in each group, treatment period during which participants will be randomized into 1 of 5 groups (4 will receive one of the LY2189265 doses, 1 group will receive placebo), and safety follow up. Maximum of 9 study visits are planned. Study drug (LY2189265 or placebo) will be administered once weekly via subcutaneous (SC) injections. Rescue intervention was allowed after randomization for those participants whose hyperglycemia reached pre-defined unacceptable high values. Participants on rescue therapy remained in the study and continued to receive study drug. Participants who received rescue therapy were included in the analysis population, but only measurements obtained prior to the beginning of rescue therapy were included in specified efficacy analyses.
A 3-mg LY2189265 dose was discontinued and replaced with the 1.5 mg dose based on dose finding Study H9X-MC-GBCF; NCT00734474. Except where noted, data summaries from the 3 discontinued 3-mg LY2189265 participants (n=3) are not included due to the small number of participants and the short treatment duration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265: 0.1 milligram (mg), subcutaneous (SC), once weekly (QW)
Drug: LY2189265 and Lifestyle Measures
LY2189265: 0.5 milligram (mg), subcutaneous (SC), once weekly (QW)
Drug: LY2189265 and Lifestyle Measures
LY2189265: 1.0 milligram (mg), subcutaneous (SC), once weekly (QW)
Drug: LY2189265 and Lifestyle Measures
LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
Drug: LY2189265 and Lifestyle Measures
Placebo: subcutaneous (SC) once weekly (QW)
Drug: Placebo solution and Lifestyle Measures
Drug page: Dulaglutide
Subcutaneous injection once-weekly for up to 12 weeks
Also known as: Dulaglutide
Subcutaneous injection once-weekly for up to 12 weeks
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Least Squares (LS) means of change from baseline for glycosylated hemoglobin (HbA1c) were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HbA1c as covariate.
Time frame: Baseline, 12 weeks
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline glycosylated hemoglobin (HbA1c) as covariate.
Time frame: Baseline, 4 weeks, 8 weeks
Change From Baseline in Fasting Blood Glucose
Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline fasting glucose as covariate.
Time frame: Baseline, 12 weeks
Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%
Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7.0% or ≤6.5% were compared across treatment arms using the Cochran-Armitage trend test.
Time frame: 12 weeks
Change From Baseline in Daily Mean Blood Glucose Values From the 7-point Self Monitored Blood Glucose (SMBG) Profiles
Change from baseline in mean daily blood glucose values were measured with a 7-point self-monitored blood glucose (SMBG) profile over a 24-hour period in the 7-day period prior to each visit. The 7-point SMBG profile consisted of preprandial blood glucose measures before the morning, midday, and evening meals; blood glucose measures 2 hours after the start of the morning, midday, and evening meals; and the fasting blood glucose obtained the following morning. Mean at 12 weeks was assessed in all treatment groups. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and as covariate.
Time frame: Baseline, 12 weeks
Change From Baseline in Beta-cell Function (HOMA2-%B)
Change from baseline in beta (β)-cell function (HOMA2-%B) was assessed by using the homeostatic model assessment (HOMA) to quantify β-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B), as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HOMA2-%B as covariate.
Time frame: Baseline, 12 weeks
Change From Baseline in Insulin Sensitivity (HOMA2-%S)
Change from baseline in insulin sensitivity (HOMA2-%S) was assessed by using the homeostatic model assessment (HOMA) to quantify insulin sensitivity. HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state insulin sensitivity (%S), as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HOMA2-%S as covariate.
Time frame: Baseline, 12 weeks
Change From Baseline in Electrocardiograms (ECGs) - Fridericia-corrected QT (QTcF) and PR Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. The PR segment begins at the endpoint of the P wave and ends at the onset of the QRS complex. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
Time frame: Baseline, 12 weeks
Change From Baseline in Electrocardiograms (ECGs) - Heart Rate
Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
Time frame: Baseline, 12 weeks
Change From Baseline in Pulse Rate
Sitting pulse rate was measured. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
Time frame: Baseline, 12 weeks
Change From Baseline in Blood Pressure (BP)
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
Time frame: Baseline, 12 weeks
Number of Participants With Self-reported Hypoglycemic Events
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined an event during which typical symptoms of hypoglycemia were accompanied by a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), or nocturnal (defined as any hypoglycemic event that occurred between bedtime and breakfast with a measured blood glucose of ≤3.9 mmol/L). Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 12 weeks
Rate of Self-reported Hypoglycemic Events
Hypoglycemic events (HE) were classified as severe (defined as events requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined an event during which typical symptoms of hypoglycemia were accompanied by a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), or nocturnal (defined as any HE that occurred between bedtime and breakfast with a measured blood glucose of ≤3.9 mmol/L). Participant reports of HE were collected at the beginning of each visit starting at Baseline and the annualized rate was reported. Least Squares (LS) means rates were adjusted for pre-study therapy, country, and baseline body mass index. A summary of AEs regardless of causality is located in the Reported AEs module. Some model-adjusted LS means are less than 0 and may be interpreted as very low rates.
Time frame: Baseline through 12 weeks
Treatment Emergent Adverse Events
A treatment emergent adverse event is any untoward medical occurrence that either occurs or worsens at any time after the first injection of study drug following randomization and which does not necessarily have to have a causal relationship. The number of participants with one or more treatment emergent adverse event was reported. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 12 weeks
Change From Baseline in Body Weight
Least Squares (LS) means was calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
Time frame: Baseline, 12 weeks
Antibody Production and Effects to LY2189265
LY2189265 anti-drug antibodies (ADA) were assessed at baseline, 4 and 12 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation (16 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized.
Time frame: Baseline, 4 weeks, 12 weeks, 16 weeks
Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265
The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve (AUC) from zero to 168 hours). Evaluable PK concentrations from the 4 week, 8 week, and 12 week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
Time frame: 4 weeks, 8 weeks, 12 weeks
| Milestone | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|---|
| Started | 35 | 34 | 34 | 29 | 3 | 32 |
| Received at least one dose of study drug | 35 | 34 | 34 | 29 | 3 | 32 |
| Completed | 33 | 31 | 34 | 25 | 0 | 29 |
| Not completed | 2 | 3 | 0 | 4 | 3 | 3 |
| Withdrew: Dose discontinued per sponsor decision | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 2 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 1 |
Least Squares (LS) means of change from baseline for glycosylated hemoglobin (HbA1c) were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HbA1c as covariate.
| percentage of glycosylated hemoglobin | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) | -0.37 ± 0.11 | -0.89 ± 0.12 | -1.03 ± 0.11 | -1.04 ± 0.13 | 0.01 ± 0.13 |
Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline glycosylated hemoglobin (HbA1c) as covariate.
| percentage of glycosylated hemoglobin | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Week 4 (n=35, n=34, n=34, n=25, n=29) | -0.28 ± 0.09 | -0.51 ± 0.09 | -0.46 ± 0.08 | -0.53 ± 0.10 | -0.01 ± 0.10 |
| Week 8 (n=35, n=30, n=33, n=24, n=28) | -0.33 ± 0.10 | -0.74 ± 0.10 | -0.78 ± 0.10 | -0.90 ± 0.12 | -0.00 ± 0.11 |
Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline fasting glucose as covariate.
| milligrams per deciliter (mg/dL) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Fasting Blood Glucose | -11.59 ± 4.09 | -30.31 ± 4.26 | -33.73 ± 4.18 | -37.49 ± 4.78 | -3.78 ± 4.44 |
Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7.0% or ≤6.5% were compared across treatment arms using the Cochran-Armitage trend test.
| percentage of participants | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| HbA1c levels <7.0% (n=34, n=30, n=32, n=21, n=28) | 47.1 | 73.3 | 75.0 | 71.4 | 21.4 |
| HbA1c levels ≤6.5% (n=34, n=30, n=32, n=21, n=28) | 14.7 | 53.3 | 50.0 | 52.4 | 7.1 |
Change from baseline in mean daily blood glucose values were measured with a 7-point self-monitored blood glucose (SMBG) profile over a 24-hour period in the 7-day period prior to each visit. The 7-point SMBG profile consisted of preprandial blood glucose measures before the morning, midday, and evening meals; blood glucose measures 2 hours after the start of the morning, midday, and evening meals; and the fasting blood glucose obtained the following morning. Mean at 12 weeks was assessed in all treatment groups. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and as covariate.
| milligrams per deciliter (mg/dL) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Daily Mean Blood Glucose Values From the 7-point Self Monitored Blood Glucose (SMBG) Profiles | -15.77 ± 4.74 | -32.21 ± 4.88 | -42.46 ± 4.68 | -44.79 ± 5.46 | -6.12 ± 5.05 |
Change from baseline in beta (β)-cell function (HOMA2-%B) was assessed by using the homeostatic model assessment (HOMA) to quantify β-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B), as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HOMA2-%B as covariate.
| percentage of HOMA2-%B | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Beta-cell Function (HOMA2-%B) | 13.18 ± 6.76 | 31.66 ± 7.04 | 39.04 ± 7.64 | 29.29 ± 8.11 | -2.06 ± 7.44 |
Change from baseline in insulin sensitivity (HOMA2-%S) was assessed by using the homeostatic model assessment (HOMA) to quantify insulin sensitivity. HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state insulin sensitivity (%S), as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HOMA2-%S as covariate.
| percentage of HOMA2-%S | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Insulin Sensitivity (HOMA2-%S) | -2.41 ± 6.62 | 6.10 ± 6.92 | -4.80 ± 7.44 | 12.98 ± 7.95 | 0.58 ± 7.34 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. The PR segment begins at the endpoint of the P wave and ends at the onset of the QRS complex. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
| millisecond (msec) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Fridericia-corrected QT (QTcF) Interval | 1.34 ± 2.09 | -1.18 ± 2.11 | 4.56 ± 2.01 | -0.63 ± 2.33 | 0.70 ± 2.19 |
| PR Interval | 3.22 ± 2.20 | 4.57 ± 2.23 | -0.55 ± 2.15 | 2.83 ± 2.46 | -0.89 ± 2.33 |
Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
| beats per minute (bpm) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Electrocardiograms (ECGs) - Heart Rate | 1.38 ± 1.48 | 1.16 ± 1.51 | 1.88 ± 1.44 | 4.18 ± 1.67 | 0.67 ± 1.58 |
Sitting pulse rate was measured. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
| beats per minute (bpm) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Pulse Rate | 0.19 ± 1.44 | 0.25 ± 1.49 | 1.02 ± 1.43 | 1.34 ± 1.65 | 1.29 ± 1.54 |
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
| millimeters of mercury (mmHg) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Sitting Systolic Blood Pressure | -2.21 ± 2.04 | 0.51 ± 2.12 | -2.57 ± 2.02 | 1.88 ± 2.33 | -0.68 ± 2.18 |
| Sitting Diastolic Blood Pressure | -0.24 ± 1.21 | 0.59 ± 1.26 | 0.42 ± 1.20 | 1.56 ± 1.39 | 1.07 ± 1.30 |
Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined an event during which typical symptoms of hypoglycemia were accompanied by a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), or nocturnal (defined as any hypoglycemic event that occurred between bedtime and breakfast with a measured blood glucose of ≤3.9 mmol/L). Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Documented Symptomatic | 0 | 2 | 2 | 3 | 0 |
| Asymptomatic | 1 | 0 | 0 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 | 0 |
| Nocturnal | 1 | 2 | 1 | 2 | 0 |
Hypoglycemic events (HE) were classified as severe (defined as events requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined an event during which typical symptoms of hypoglycemia were accompanied by a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), or nocturnal (defined as any HE that occurred between bedtime and breakfast with a measured blood glucose of ≤3.9 mmol/L). Participant reports of HE were collected at the beginning of each visit starting at Baseline and the annualized rate was reported. Least Squares (LS) means rates were adjusted for pre-study therapy, country, and baseline body mass index. A summary of AEs regardless of causality is located in the Reported AEs module. Some model-adjusted LS means are less than 0 and may be interpreted as very low rates.
| Events per participant per year | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Documented Symptomatic Hypoglycemic Rate | -0.08 ± 0.72 | 0.25 ± 0.73 | 1.68 ± 0.73 | 0.61 ± 0.79 | -0.09 ± 0.75 |
| Asymptomatic Hypoglycemic Rate | 0.19 ± 0.10 | -0.01 ± 0.10 | -0.01 ± 0.10 | 0.02 ± 0.11 | 0.01 ± 0.11 |
| Severe Hypoglycemic Rate | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Nocturnal Hypoglycemic Rate | 0.20 ± 0.62 | 0.16 ± 0.64 | 1.21 ± 0.62 | 0.21 ± 0.71 | -0.08 ± 0.67 |
A treatment emergent adverse event is any untoward medical occurrence that either occurs or worsens at any time after the first injection of study drug following randomization and which does not necessarily have to have a causal relationship. The number of participants with one or more treatment emergent adverse event was reported. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|---|
| Treatment Emergent Adverse Events | 21 | 17 | 20 | 18 | 1 | 18 |
Least Squares (LS) means was calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.
| kilogram (kg) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Body Weight | -0.19 ± 0.42 | -0.34 ± 0.43 | -1.11 ± 0.42 | -1.49 ± 0.48 | -1.38 ± 0.45 |
LY2189265 anti-drug antibodies (ADA) were assessed at baseline, 4 and 12 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation (16 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized.
| participants | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|
| Week 4 | 0 | 0 | 1 | 0 | 0 |
| Week 12 | 0 | 0 | 0 | 0 | 0 |
| Week 16 | 0 | 0 | 0 | 0 | 0 |
The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve (AUC) from zero to 168 hours). Evaluable PK concentrations from the 4 week, 8 week, and 12 week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
| nanograms*hour/milliliter (ng*h/mL) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 |
|---|---|---|---|---|---|
| Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265 | 2294 ± 1503 | 6650 ± 4356 | 11671 ± 7645 | 16649 ± 10905 | 31538 ± 20657 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.1 Milligrams (mg) LY2189265 | — | 0/35 (0%) | 20/35 (57.1%) |
| 0.5 Milligrams (mg) LY2189265 | — | 1/34 (2.9%) | 16/34 (47.1%) |
| 1.0 Milligrams (mg) LY2189265 | — | 1/34 (2.9%) | 17/34 (50%) |
| 1.5 Milligrams (mg) LY2189265 | — | 1/29 (3.4%) | 15/29 (51.7%) |
| 3.0 Milligrams (mg) LY2189265 | — | 0/3 (0%) | 1/3 (33.3%) |
| Placebo | — | 1/32 (3.1%) | 15/32 (46.9%) |
| Event | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|---|
| Abdominal distensionGastrointestinal disorders | 0/35 | 0/34 | 0/34 | 1/29 | 0/3 | 0/32 |
| Abdominal painGastrointestinal disorders | 0/35 | 0/34 | 0/34 | 1/29 | 0/3 | 0/32 |
| Pancreatitis haemorrhagicGastrointestinal disorders | 0/35 | 0/34 | 0/34 | 0/29 | 0/3 | 1/32 |
| CholelithiasisHepatobiliary disorders | 0/35 | 0/34 | 0/34 | 0/29 | 0/3 | 1/32 |
| Atrial flutterCardiac disorders | 0/35 | 0/34 | 1/34 | 0/29 | 0/3 | 0/32 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/35 | 1/34 | 0/34 | 0/29 | 0/3 | 0/32 |
| Event | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo |
|---|---|---|---|---|---|---|
| PharyngitisInfections and infestations | 2/35 | 0/34 | 0/34 | 1/29 | 1/3 | 1/32 |
| DyspepsiaGastrointestinal disorders | 2/35 | 0/34 | 1/34 | 4/29 | 0/3 | 0/32 |
| NauseaGastrointestinal disorders | 4/35 | 0/34 | 4/34 | 2/29 | 0/3 | 3/32 |
| HeadacheNervous system disorders | 1/35 | 0/34 | 4/34 | 2/29 | 0/3 | 0/32 |
| ConstipationGastrointestinal disorders | 1/35 | 2/34 | 1/34 | 3/29 | 0/3 | 1/32 |
| DiarrhoeaGastrointestinal disorders | 2/35 | 3/34 | 1/34 | 3/29 | 0/3 | 1/32 |
| NasopharyngitisInfections and infestations | 0/35 | 2/34 | 2/34 | 3/29 | 0/3 | 2/32 |
| Vulvovaginal mycotic infectionInfections and infestations | 0/24 | 0/18 | 0/18 | 0/16 | 0/3 | 1/14 |
| Abdominal distensionGastrointestinal disorders | 2/35 | 1/34 | 0/34 | 2/29 | 0/3 | 0/32 |
| VomitingGastrointestinal disorders | 1/35 | 0/34 | 0/34 | 2/29 | 0/3 | 2/32 |
Participants who received at least one dose of study drug.
| Age, Continuous(years) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 56.33 ± 9.15 | 56.91 ± 9.06 | 57.16 ± 8.76 | 57.45 ± 7.88 | 60.82 ± 7.15 | 55.03 ± 9.33 | 56.64 ± 8.78 |
| Sex: Female, Male(Participants) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 24 | 18 | 18 | 16 | 2 | 14 | 92 |
| Male | 11 | 16 | 16 | 13 | 1 | 18 | 75 |
| Race/Ethnicity, Customized(participants) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 2 | 0 | 0 | 0 | 3 |
| Asian | 4 | 5 | 5 | 4 | 0 | 5 | 23 |
| Black or African American | 1 | 1 | 0 | 1 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| White | 29 | 28 | 26 | 24 | 2 | 25 | 134 |
| Multiple | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|---|---|
| United States | 16 | 15 | 13 | 11 | 3 | 17 | 75 |
| Mexico | 5 | 5 | 4 | 4 | 0 | 5 | 23 |
| Puerto Rico | 0 | 1 | 2 | 2 | 0 | 0 | 5 |
| Spain | 2 | 3 | 1 | 1 | 0 | 1 | 8 |
| Poland | 2 | 2 | 5 | 5 | 0 | 2 | 16 |
| Croatia | 4 | 2 | 2 | 3 | 0 | 3 | 14 |
| Russian Federation | 2 | 1 | 2 | 0 | 0 | 0 | 5 |
| India | 4 | 5 | 5 | 3 | 0 | 4 | 21 |
| Body Mass Index (BMI)(kilograms/square meters (kg/m^2)) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 32.92 ± 4.75 | 32.26 ± 5.39 | 32.22 ± 4.50 | 31.04 ± 4.29 | 35.38 ± 3.96 | 32.07 ± 5.23 | 32.20 ± 4.83 |
| Duration of Diabetes(years) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 3.90 ± 3.19 | 3.72 ± 3.80 | 3.28 ± 2.54 | 4.62 ± 4.08 | 5.00 ± 3.04 | 3.91 ± 4.74 | 3.88 ± 3.68 |
| Body Weight(kilogram (kg)) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 87.08 ± 17.28 | 90.20 ± 21.34 | 86.89 ± 16.95 | 85.81 ± 18.63 | 100.90 ± 25.51 | 90.87 ± 18.94 | 88.43 ± 18.68 |
| Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin) | 0.1 Milligrams (mg) LY2189265 | 0.5 Milligrams (mg) LY2189265 | 1.0 Milligrams (mg) LY2189265 | 1.5 Milligrams (mg) LY2189265 | 3.0 Milligrams (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 7.13 ± 0.55 | 7.18 ± 0.60 | 7.28 ± 0.66 | 7.25 ± 0.43 | 7.63 ± 0.15 | 7.36 ± 0.63 | 7.24 ± 0.58 |
The record gives a start of Dec 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 4 years 11 months after primary completion. A results delay was requested in Oct 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide